Baird maintains Inspire Medical Systems at Neutral, raises price target to $77 from $73

Baird kept its Neutral rating on Inspire Medical Systems but increased its price target to $77 from $73, suggesting a 14.6% upside from the Nov 2 close of $67.21, according to the firm.

Original reporting
Published Nov 3, 2026, 11:41 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Baird maintains Inspire Medical Systems at Neutral, raises price target to $77 from $73 — source image
Decision brief

The 30-second read

$INSPBullishLow
01

Why it matters

The price target increase signals a modest upside potential, but limited catalyst depth keeps impact modest.

02

Market read

A small-cap medical device stock receives a modest analyst upgrade, offering limited trading opportunity.

03

What to watch

No mention of new product trials or regulatory milestones.

Relevance 5/10Novelty 4/10Timing: today

Background

Analyst rating changes can influence short-term price moves, especially for small-cap stocks.

Company-level read

Ticker impact

$INSPBullishMedium confidence
Context

Baird raised its price target for Inspire Medical Systems to $77 from $73, indicating a fresh analyst upgrade.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Target raise suggests improved outlook; no other catalysts present.

Market effects

None significant beyond the company.

Minimal impact on broader market.

Limited to niche medical device sector.

Counterpoint

The upgrade may be premature if upcoming clinical data disappoints.

Key entities

  • Baird

    Provided the rating upgrade and new price target.

  • Inspire Medical Systems

    Medical device maker receiving the upgraded target.

Related articles

$INSPMedAI 8/10

Inspire (INSP) Q3 2026 Earnings Call Transcript

Inspire (INSP) reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3% sequentially. The company expects stable coding framework in 2027 and a new code in 2028, with strong adoption of Inspire V. Operating loss was $28.7M, and adjusted EPS was $0.14. The company is investing in patient flow optimization and expanding market reach. According to the company, they remain confident in their path to growth.

$INSPMed

Inspire: Q3 Earnings Snapshot

Inspire Medical Systems (INSP) reported a Q3 loss of $24.4M, or 84 cents per share, but adjusted earnings of 14 cents per share, beating estimates. Revenue was $206.7M, also topping forecasts. The company expects full-year earnings of $1.20-$1.40 per share and revenue of $850M-$860M.

$INSPMed

Inspire Medical Systems Q3 Earnings Call Highlights

Inspire Medical Systems (INSP) reported Q3 earnings, estimating coding and reimbursement challenges reduced results by $30M and may impact 2026 results by $120M. The company expects revenue growth in Q4 and low-single-digit growth in 2027, citing stable coding and investments. Inspire highlighted a new CPT code for its Inspire V device and ongoing development of Inspire VI. Management discussed clinical evidence supporting their therapy and plans to invest in patient access and education.

$INSPHighAI 8/10

Inspire Medical Q3 2026 slides: reimbursement clarity ahead, growth reset

Inspire Medical Systems reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3.0% sequentially. The company cited reimbursement challenges as the primary headwind. Shares rose 1.83% in after-hours trading. Inspire highlighted its market position and long-term growth potential, despite near-term slowdowns. The company expects full-year 2026 revenue of $850M-$860M, down from 2025 levels.